07:00 , Jun 22, 2009 |  BioCentury  |  Finance

Ebb & Flow

If Symphony Capital had been able to make good on the original buyback terms of its 2006 deal with Alexza Pharmaceuticals Inc. (NASDAQ:ALXA), Symphony would have doubled its money. But times being what they are,...
07:00 , May 26, 2008 |  BioCentury  |  Finance

Midlife crisis

Investor enthusiasm for European biotech is falling away just as the industry's capital demand continues to rise in response to a plethora of maturing clinical programs. Investors are shying away from mid-stage companies, preferring either...